|
| 37098956 | Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization. | | 2023 |
| 38019653 | High frequency of HIV precursor-target-specific B cells in sub-Saharan populations. | | 2023 |
| 37896806 | Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. | | 2023 |
| 37639457 | Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes. | | 2023 |
| 37561630 | Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes. | Cell Rep | 2023 |
| 37781590 | Immune memory shapes human polyclonal antibody responses to H2N2 vaccination. | | 2023 |
| 37406137 | Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. | Sci Transl Med | 2023 |
| 37147136 | Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection. | | 2023 |
| 36895286 | Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. | | 2023 |
| 37075127 | Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. | Sci Transl Med | 2023 |
| 37075126 | An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. | | 2023 |
| 36875204 | Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort. | Influenza Other Respir Viruses | 2023 |
| 37001964 | Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. | | 2023 |
| 37436899 | HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide. | Cell Rep | 2023 |
| 37300931 | Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. | EBioMedicine | 2023 |
| 36993183 | Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming. | | 2023 |
| 36599369 | Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19. | Nature | 2023 |
| 37544326 | Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. | Lancet Infect Dis | 2023 |
| 37224227 | A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. | | 2023 |
| 34812653 | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. | Science | 2022 |
| 36306784 | Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. | Immunity | 2022 |
| 35589938 | Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. | Scientific Reports | 2022 |
| 36357712 | Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. | Nat Microbiol | 2022 |
| 35447072 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. | Cell | 2022 |
| 36356572 | Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. | Immunity | 2022 |
| 36094485 | Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children. | J Acquir Immune Defic Syndr | 2022 |
| 36093348 | Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination. | | 2022 |
| 35759653 | Early human B cell signatures of the primary antibody response to mRNA vaccination. | Proceedings of the National Academy of Sciences of the United States of America | 2022 |
| 36091040 | The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection. | Front Immunol | 2022 |
| 35441174 | Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. | medRxiv | 2022 |
| 36284200 | Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. | Scientific Reports | 2022 |
| 35378757 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | bioRxiv | 2022 |
| 35489332 | Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite. | Structure | 2022 |
| 36128909 | Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia. | Br J Haematol | 2022 |
| 35547849 | Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis. | | 2022 |
| 36257313 | Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. | Cell | 2022 |
| 35921449 | Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. | New England Journal of Medicine | 2022 |
| 35783486 | Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. | eClinicalMedicine | 2022 |
| 36317783 | Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. | New England Journal of Medicine | 2022 |
| 36523413 | Respiratory Virus Circulation during the First Year of the COVID-19 Pandemic in the Household Influenza Vaccine Evaluation (HIVE) Cohort. | medRxiv | 2022 |
| 36517467 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | Nat Commun | 2022 |
| 36582240 | Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings. | Front Immunol | 2022 |
| 36454825 | Vaccination induces HIV broadly neutralizing antibody precursors in humans. | Science | 2022 |
| 34213402 | Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. | Hum Vaccin Immunother | 2022 |
| 34562096 | Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. | Journal of Infectious Diseases | 2022 |
| 35233581 | Influenza vaccination and single cell multiomics reveal sex dimorphic immune imprints of prior mild COVID-19. | medRxiv | 2022 |
| 35134995 | Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. | Journal of Infectious Diseases | 2022 |
| 35115707 | A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. | Nature Medicine | 2022 |
| 35081293 | Homologous and Heterologous Covid-19 Booster Vaccinations. | N Engl J Med | 2022 |
| 34471908 | Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry. | STAR Protocols | 2021 |